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increased by $10 in each of the 3 tiers. The patient population
was limited to individuals that were continuously enrolled for
both 1998 and 1999, in addition to having had a minimum of
three prescription claims for a STATIN prior to the third quarter
of 1998 and a minimum of three STATIN claims in 1999. Basic
descriptive statistics such as means and standard deviations were
used to describe the population. RESULTS: All four measures
indicate that after the $10 dollar increase in prescription copay-
ment STATIN compliance decreased. The greatest change in
compliance was found in the consistence measure, in which
patients on average were 83% (std. 15%) consistent in 1998 as
compared to 73% (std. 23%) in 1999. Patients mean MPR
dropped slightly from 0.81 (std. 0.17) in 1998 to 0.80 (std. 0.20)
in 1999. The mean number of gaps, deﬁned as greater than 15
days without a STATIN, increased by 0.19 gaps per person in
1999. Similar with the other three compliance measures the
maximum gap in STATIN therapy increased from 26.13 days
(std. 29.10) in 1998 to 31.81 days (std. 35.79) in 1999. CON-
CLUSIONS: Descriptively all four measures of medication
taking behavior indicate that an increase in copayment results in
a decrease in STATIN compliance.
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OBJECTIVES: To review the challenges for conducting eco-
nomic evaluations of pharmacogenomic-based interventions
(PGx) by: 1) identifying key factors that may inﬂuence cost-
effectiveness; 2) describing how the “value” of PGx can be mea-
sured using willingness-to-pay approaches; and 3) discussing 
speciﬁc examples of the challenges faced by industry and regu-
lators in valuing and implementing PGx. METHODS: Data was
obtained from systematic searches of the Medline literature,
interviews with key participants from industry and government,
and our analyses conducted for biotech companies and the U.S.
Food and Drug Administration. RESULTS: There are very few
published cost-effectiveness analyses of PGx, and few analyses
measuring willingness-to-pay for these new technologies. Much
of the data needed to evaluate PGx are uncertain or complex to
model, particularly 1) what populations should be tested; 2) con-
current development of test and drug combinations; 3) model-
ing the development of genomic risk proﬁles and test accuracy;
4) considering long-term and induced effects, and 5) evaluating
how the value of PGx will be interpreted by patients, providers,
insurers, and regulators. We discuss case studies of these chal-
lenges and provide examples of how they might be resolved.
CONCLUSIONS: The expanded use of pharmacogenomics
offers many potential clinical beneﬁts but also many economic
challenges. Academic researchers must work together with
industry and government to address these challenges if the
promises of pharmacogenomics are to be achieved.
